Contemporary Clinical Trials

Papers
(The H4-Index of Contemporary Clinical Trials is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease67
Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials60
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the 50
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) study: Rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline50
The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design50
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change38
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis a35
COVID-19 vaccines: Considering sex differences in efficacy and safety34
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial32
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse31
Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials30
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome29
Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol29
Using digital technologies in clinical trials: Current and future applications28
Study to promote innovation in rural integrated telepsychiatry (SPIRIT): Rationale and design of a randomized comparative effectiveness trial of managing complex psychiatric disorders in rural primary26
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT13783126
Development of a core outcome set for pediatric critical care outcomes research26
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States26
Implementation of platform trials in the COVID-19 pandemic: A rapid review24
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers24
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation24
Sense2Stop: A micro-randomized trial using wearable sensors to optimize a just-in-time-adaptive stress management intervention for smoking relapse prevention24
Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications23
0.021666765213013